علاج داء السكري المناعي الذاتي الكامن في البالغين (LADA)

References

DOI: 10.4093/dmj.2018.0190

• Considering the autoimmune response in LADA, which generally lead to the β-cell impairment, insulin therapy should ideally represent the treatment of choice in these subjects.
• To date, according to the outcomes of large randomized clinical trials, physicians tend to prescribe insulin therapy at an earlier stage in patients with LADA, regardless C-peptide levels and residual β-cell function.
• To date, evidence shows that patients with LADA should be treated with insulin at an earlier stage, whereas sulfonylureas are discouraged due to their effects on β-cells.
• Therefore, it is recommended that sulfonylureas should be avoided in patients with LADA/SPIDDM.